PolTREG is at the forefront of developing innovative cell therapies specifically targeting autoimmune diseases, which occur when the immune system mistakenly attacks the body’s own tissues. The company focuses on T regulatory cells (Tregs), which are a specialized type of immune cell that can help modulate the immune response. PolTREG's pipeline includes three clinical assets, notably PTG-007, which is being investigated as a disease-modifying treatment for conditions such as Type 1 Diabetes and Multiple Sclerosis. The company aims to halt the progression of these diseases, particularly in their early stages, and improve the quality of life for patients with more advanced conditions. 

In addition to its proprietary Treg therapies, PolTREG is also exploring next-generation engineered Tregs, including CAR-Tregs and TCR-Tregs, which represent a significant advancement in the field of cell therapy. These therapies are designed to enhance the immunosuppressive capabilities of Tregs, potentially offering new treatment options for chronic and currently incurable autoimmune diseases. With a robust clinical pipeline and a commitment to advancing the science of Treg therapies, PolTREG is positioned to make a substantial impact in the treatment landscape for autoimmune disorders.

Poland

PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS).
PolTREG has very promising results regarding the safety and efficacy of TREGS therapy (completed phase I/II clinical trials in T1D and phase I in MS), ready for the next phase of trials. The company is after EMA Scientific Advice procedure.

PolTREG

Company Details